847373-09-5

Basic information

• Product Name: 3-Pyridinecarboxylic acid, 4-[(4-bromo-2-chlorophenyl)amino]-5,6-dichloro-, methyl ester
• CAS NO: 847373-09-5
• Molecular Formula: C13H8BrCl3N2O2
• Molecular Weight: 410.482
• Mol File: 847373-09-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-Pyridinecarboxylic acid, 4-[(4-bromo-2-chlorophenyl)amino]-5,6-dichloro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylic acid, 4-[(4-bromo-2-chlorophenyl)amino]-5,6-dichloro-, methyl ester(847373-09-5)
• EPA Substance Registry System: 3-Pyridinecarboxylic acid, 4-[(4-bromo-2-chlorophenyl)amino]-5,6-dichloro-, methyl ester(847373-09-5)

Safety Data

• Hazardous Substances Data: 847373-09-5(Hazardous Substances Data)

Upstream product

• 846541-71-7 ethyl 5-chloro-4,6-dihydroxynicotinate 
• 181261-73-4 ethyl 4,5,6-trichloronicotinate 
• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 847608-28-0 4,5,6-trichloronicotinic acid 
• 847373-08-4 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 847373-10-8 6-azido-4-(4-bromo-2-chloro-phenylamino)-5-chloro-nicotinic acid methyl ester 
• 874353-12-5 4-(4-bromo-2-chlorophenylamino)-5-chloro-6-methoxynicotinic acid 

Relevant articles and documents

INHIBITORS OF MEK

This invention concerns to N-(2-aylamino) aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.

Heterocyclic inhibitors of MEK and methods of use thereof

Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9 and R10, W and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.